Ozempic® & Weight Loss

Ozempic is FDA-approved for type 2 diabetes, not weight loss. While many patients taking Ozempic do lose weight, prescribing it off-label for weight management creates insurance coverage issues, delivers a lower dose than what was studied for weight loss, and doesn't align with FDA indications. At PEAK, we prescribe Wegovy for weight loss — the same semaglutide molecule at the FDA-approved therapeutic dose (2.4 mg) for chronic weight management.

Both contain semaglutide and are made by Novo Nordisk. The key differences: Ozempic is approved for type 2 diabetes (max dose 2.0 mg), while Wegovy is approved for chronic weight management (maintenance dose 2.4 mg). Wegovy was studied in dedicated weight loss trials (STEP program) and also has FDA approval for cardiovascular risk reduction. For a detailed comparison, see our Wegovy vs Ozempic guide.

No. Most insurance plans will not cover Ozempic for weight loss if you don't have type 2 diabetes, because it's not FDA-approved for that indication. Insurance formularies match medications to their approved uses. Wegovy, which is FDA-approved for weight management, has a much better path to coverage when prescribed for weight loss. PEAK accepts Anthem, Cigna, Aetna, UnitedHealthcare, Sentara, and TRICARE commercial plans, and does not accept Medicare or Medicaid plans. At PEAK, we verify your insurance benefits before your first visit and handle all prior authorization for you.

The most common side effects of semaglutide (whether Ozempic or Wegovy) are gastrointestinal: nausea, diarrhea, vomiting, constipation, and decreased appetite. These are typically most noticeable when starting the medication or increasing the dose and tend to improve over time. At PEAK, our clinical team provides guidance on managing nausea and GI side effects. Serious but rare risks include pancreatitis and thyroid C-cell tumors (seen in animal studies). Semaglutide carries a boxed warning: it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Your clinician will review your full medical history to ensure semaglutide is safe for you.

If you're taking Ozempic for diabetes and weight loss is a beneficial side effect, there may be no need to switch. But if weight management is your primary goal and you don't have diabetes, switching to Wegovy is the clinically appropriate step. You'll get the FDA-studied weight loss dose (2.4 mg), better insurance coverage for the weight loss indication, and access to manufacturer savings programs designed for weight management patients. Since both medications are semaglutide, the transition is straightforward. Learn more about switching to FDA-approved semaglutide.

Ozempic contains semaglutide (a GLP-1 receptor agonist), while Mounjaro and Zepbound contain tirzepatide (a dual GIP/GLP-1 receptor agonist). Tirzepatide targets two metabolic pathways instead of one, which has shown greater average weight loss in clinical trials. Ozempic and Mounjaro are both for diabetes; Wegovy and Zepbound are the corresponding weight loss formulations. See our comparisons: Zepbound vs Wegovy and Zepbound vs Mounjaro.